Home - Calico
Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program
News & Media - Calico
Welcome to the Calico media center. Please find below features on our R&D efforts as well as our official press releases. For media inquiries, please email [email protected].
Collaborator Profiles - Calico
Calico and AbbVie’s Fosigotifator Selected for FDA’s New START Pilot Program Since 2015, Calico and the Broad Institute of MIT and Harvard have partnered to investigate the biology …
Calico Stories - Calico
Cardiometabolic diseases are an increasing global health burden. And Calico scientists, led by Madeleine Cule, are working with the University of Westminster and … Keep Reading
Susan Uptain, Ph.D. - Calico
In her role as Head of Project Team Leadership and Regulatory, Susan provides oversight and direction for Calico’s drug discovery and development programs as they transition from …
Alveolar regeneration by airway secretory-cell-derived p63
Sep 3, 2024 · Zan Lv, Zixin Liu, Kuo Liu, Xiuyu Lin, Wenjuan Pu, Yan Li, Huan Zhao, Ying Xi, Pengfei Sui, Andrew E Vaughan, Astrid Gillich, and Bin Zhou
Patients - Calico
Calico registers interventional clinical trials conducted in patients on www.clinicaltrials.gov. If you are a patient interested in one of our clinical trials, please visit www.clinicaltrials.gov to learn …
Drug Development - Calico
Calico Stories December 4, 2023 Probing the entire genome to pinpoint novel immunotherapy targets
Michael Lenardo, M.D. - Calico
Mike joined Calico in 2024 as Chief Scientific Officer, a role in which he is responsible for the company’s overall research strategy. He is establishing a lab that will address the aging …
Contact Us - Calico
Calico is currently seeking exceptional candidates who share our passion for understanding the science of aging and developing therapeutics to address age-related diseases. Explore Careers